• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Safety and immunogenicity of rabies vaccine as 4 - dose Essen Intramuscular regimen for post exposure prophylaxis: A non - randomized, comparative controlled study.狂犬病疫苗作为暴露后预防的 4 剂 Essen 肌内注射方案的安全性和免疫原性:一项非随机、对照的比较研究。
Hum Vaccin Immunother. 2021 Aug 3;17(8):2554-2559. doi: 10.1080/21645515.2021.1883388. Epub 2021 Feb 23.
2
Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.在6至17岁中国儿童及50岁以上成年人中,采用萨格勒布2-1-1或5剂埃森方案的纯化鸡胚细胞狂犬病疫苗的免疫原性和安全性:一项随机开放标签研究。
Hum Vaccin Immunother. 2015;11(2):435-42. doi: 10.4161/21645515.2014.994460.
3
Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).根据两种不同模拟暴露后肌肉注射方案(萨格勒布方案与埃森方案)接种纯化鸡胚细胞狂犬病疫苗(PCECV)的免疫原性和安全性的比较研究。
Hum Vaccin Immunother. 2015;11(2):428-34. doi: 10.4161/21645515.2014.995059.
4
Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China.中国多中心横断面研究:4 剂 Essen 肌内注射狂犬病暴露后预防方案的免疫原性。
Travel Med Infect Dis. 2024 Jul-Aug;60:102735. doi: 10.1016/j.tmaid.2024.102735. Epub 2024 Jul 9.
5
Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.在印度生产的新型纯化鸡胚细胞狂犬病疫苗Vaxirab-N(皮特曼-摩尔株)的安全性和免疫原性研究。
Hum Vaccin Immunother. 2014;10(1):120-5. doi: 10.4161/hv.26456. Epub 2013 Sep 12.
6
Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.狂犬病中和抗体在第 0 天和第 21 天接受 2 剂皮内剂量用于暴露前预防。
Vaccine. 2013 Mar 25;31(13):1748-51. doi: 10.1016/j.vaccine.2013.01.035. Epub 2013 Jan 29.
7
Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.在暴露后人群中,采用萨格勒布方案或埃森方案接种纯化 vero 细胞培养狂犬病疫苗(Speeda)后的免疫原性、安全性及抗体持久性。
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-8. doi: 10.1080/21645515.2017.1279770. Epub 2017 Jan 25.
8
A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).鸭胚纯化疫苗(PDEV,Vaxirab)与鸡胚纯化疫苗(PCEC,Rabipur)和vero 细胞狂犬病疫苗(PVRV,Verorab)的安全性和免疫原性比较研究。
Vaccine. 2009 Dec 10;28(1):148-51. doi: 10.1016/j.vaccine.2009.09.090. Epub 2009 Oct 8.
9
Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.在健康的中国受试者中,根据萨格勒布 2-1-1 或 5 剂埃森方案,使用纯化vero 细胞狂犬病疫苗的免疫原性和安全性:一项随机、双盲、阳性对照的 3 期临床试验。
Hum Vaccin Immunother. 2021 Feb 1;17(2):351-357. doi: 10.1080/21645515.2020.1778408. Epub 2020 Aug 12.
10
A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.一项随机、开放性标签研究,旨在证明在中国人中,采用萨格勒布方案(2-1-1)接种纯化鸡胚细胞狂犬病疫苗与埃森方案相比具有非劣效性。
Hum Vaccin Immunother. 2014;10(10):2805-12. doi: 10.4161/21645515.2014.972773.

引用本文的文献

1
Antibody Persistence of Human Diploid Cell Rabies Vaccine Administrated Using the Four-Versus Five-Dose Essen Intramuscular Regimen in Post-Exposure Prophylaxis: A Prospective Cohort Study Among the Chinese Population.人二倍体细胞狂犬病疫苗采用四剂与五剂埃森肌内注射方案进行暴露后预防接种后的抗体持久性:一项针对中国人群的前瞻性队列研究
Vaccines (Basel). 2025 Feb 21;13(3):215. doi: 10.3390/vaccines13030215.
2
A prospective study on safety and clinical efficacy of rabies biologicals in paediatric patients with category III animal exposure.狂犬病生物制品在Ⅲ级动物暴露儿科患者中的安全性和临床疗效的前瞻性研究。
Clin Exp Vaccine Res. 2025 Jan;14(1):59-66. doi: 10.7774/cevr.2025.14.e1. Epub 2025 Jan 13.
3
Randomized Controlled Trial of the Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Postexposure Zagreb Regimen With Human Rabies Immunoglobulin in Adults in Thailand.泰国成人中使用模拟的暴露后萨格勒布方案联合人狂犬病免疫球蛋白对无血清纯化Vero细胞狂犬病疫苗(PVRV-NG2)的免疫原性和安全性进行的随机对照试验。
Open Forum Infect Dis. 2024 Oct 25;11(11):ofae633. doi: 10.1093/ofid/ofae633. eCollection 2024 Nov.
4
Tracking lethal threat: in-depth review of rabies.追踪致命威胁:狂犬病深度综述。
Open Vet J. 2023 Nov;13(11):1385-1399. doi: 10.5455/OVJ.2023.v13.i11.1. Epub 2023 Nov 30.
5
Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.新型三剂重组纳米颗粒狂犬病 G 蛋白疫苗作为模拟暴露后免疫接种的安全性和免疫原性:一项随机、对照、多中心、III 期临床研究。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4239-4245. doi: 10.1080/21645515.2021.1957413. Epub 2021 Sep 9.

本文引用的文献

1
Estimating the global burden of endemic canine rabies.估算地方性犬类狂犬病的全球负担。
PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709. doi: 10.1371/journal.pntd.0003709. eCollection 2015 Apr.
2
Compliance to anti-rabies vaccination in post-exposure prophylaxis.暴露后预防中狂犬病疫苗接种的依从性。
Indian J Public Health. 2015 Jan-Mar;59(1):58-60. doi: 10.4103/0019-557X.152867.
3
WHO Expert Consultation on Rabies. Second report.世界卫生组织狂犬病专家磋商会。第二次报告。
World Health Organ Tech Rep Ser. 2013(982):1-139, back cover.
4
Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices.狂犬病暴露后预防使用减毒(4 剂)疫苗接种方案:免疫实践咨询委员会的建议。
MMWR Recomm Rep. 2010 Mar 19;59(RR-2):1-9.
5
Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals.推荐 4 剂次人用狂犬病暴露后预防疫苗接种程序用于既往未接种过疫苗的个体。
Vaccine. 2009 Nov 27;27(51):7141-8. doi: 10.1016/j.vaccine.2009.09.029.
6
A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).鸭胚纯化疫苗(PDEV,Vaxirab)与鸡胚纯化疫苗(PCEC,Rabipur)和vero 细胞狂犬病疫苗(PVRV,Verorab)的安全性和免疫原性比较研究。
Vaccine. 2009 Dec 10;28(1):148-51. doi: 10.1016/j.vaccine.2009.09.090. Epub 2009 Oct 8.
7
An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects.一种新型吸附人二倍体细胞狂犬病疫苗(Rabivax)在印度受试者中的免疫原性、安全性及上市后监测
Hum Vaccin. 2008 Jul-Aug;4(4):275-9. doi: 10.4161/hv.4.4.5588.
8
A comparative study on the immunogenicity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac-N): a randomized simulated post-exposure study in healthy volunteers.印度(Vaxirab)和瑞士(Lyssavac-N)生产的纯化鸭胚疫苗(PDEV)免疫原性、安全性和耐受性的比较研究:健康志愿者的随机模拟暴露后研究
Vaccine. 2007 Dec 5;25(50):8405-9. doi: 10.1016/j.vaccine.2007.10.002. Epub 2007 Oct 22.
9
An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey.印度动物咬伤的流行病学研究:世界卫生组织赞助的全国多中心狂犬病调查结果
J Commun Dis. 2006 Mar;38(1):32-9.
10
Re-evaluating the burden of rabies in Africa and Asia.重新评估非洲和亚洲的狂犬病负担。
Bull World Health Organ. 2005 May;83(5):360-8. Epub 2005 Jun 24.

狂犬病疫苗作为暴露后预防的 4 剂 Essen 肌内注射方案的安全性和免疫原性:一项非随机、对照的比较研究。

Safety and immunogenicity of rabies vaccine as 4 - dose Essen Intramuscular regimen for post exposure prophylaxis: A non - randomized, comparative controlled study.

机构信息

Department of Community Medicine, Kempegowda Institute of Medical Sciences (KIMS), Bangalore, India.

Community Processes and Comprehensive Primary Health Care division, National Health Systems Resource Centre, New Delhi, India.

出版信息

Hum Vaccin Immunother. 2021 Aug 3;17(8):2554-2559. doi: 10.1080/21645515.2021.1883388. Epub 2021 Feb 23.

DOI:10.1080/21645515.2021.1883388
PMID:33621471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8475558/
Abstract

: World Health Organization has recommended that in healthy persons with category III exposures, who receive wound care and rabies immunoglobulin infiltration, a vaccine regimen consisting of 4 doses administered intramuscularly on days 0, 3, 7, and 14 can be used as an alternative to the 5-dose intramuscular regimen.: To assess the clinical safety and immunogenicity of rabies vaccine administered as 4-dose Essen intramuscular regimen for post-exposure prophylaxis.: A non-randomized, comparative, controlled study was conducted at the anti-rabies clinic, KIMS Hospital and Research Center, Bangalore, India. The study subjects were divided into study group i.e., 4-dose intramuscular regimen, and control group i.e., 5-dose intramuscular regimen, and were given post-exposure prophylaxis. All subjects were followed for any adverse drug events. Rabies virus neutralizing antibodies was determined on day 14, 90 & 180 at the WHO collaborating center, NIMHANS, Bangalore, India to assess the immunogenicity.: The present study included 70 adult animal bite victims, 35 each in study group and control group. The incidence of ADEs was 7.8% in 4-dose Essen group and 7.0% in 5-dose Essen group;the difference between them was not significant ( > .05). Similarly, all the subjects in both the groups had protective antibody titers of ≥ 0.5 IU/mL (100% seroprotective) from day 14 till day 180; the difference between two groups was also not significant ( > .05).: The 4-dose intramuscular Essen post-exposure prophylaxis regimen was found to be clinically safe and immunogenic.

摘要

世界卫生组织建议,对于类别 III 暴露的健康人群,在接受伤口护理和狂犬病免疫球蛋白浸润后,可以使用包含 4 剂肌肉注射的疫苗方案,在 0、3、7 和 14 天进行,作为 5 剂肌肉注射方案的替代方案。

评估狂犬病疫苗以 4 剂 Essen 肌肉内方案用于暴露后预防的临床安全性和免疫原性。

在印度班加罗尔的 KIMS 医院和研究中心的狂犬病诊所进行了一项非随机、对照、对照研究。研究对象分为研究组(即 4 剂肌肉内方案)和对照组(即 5 剂肌肉内方案),并给予暴露后预防。所有受试者均随访任何不良药物事件。在印度班加罗尔的 NIMHANS,世界卫生组织合作中心,在第 14、90 和 180 天测定狂犬病病毒中和抗体,以评估免疫原性。

本研究包括 70 名成年动物咬伤受害者,每组 35 名。4 剂 Essen 组的 ADE 发生率为 7.8%,5 剂 Essen 组为 7.0%;两者之间的差异无统计学意义(>.05)。同样,两组所有受试者的保护性抗体滴度均从第 14 天到第 180 天≥0.5 IU/ml(100%血清保护性);两组之间的差异也无统计学意义(>.05)。

4 剂肌肉内 Essen 暴露后预防方案被认为是安全且具有免疫原性的。